The name Leerink Swann is familiar. Their website is suggestive of a heavyweight player.
They seem to have researched Insmed. My gut feeling is that they must know about the dog toxicity study. Assuming they do, I would have expected a heavyweight player to have put their plan to cover Insmed on hold until they were sure there wouldn't be any bad news from the toxicity study.
I assume this is the same Leerink Swann that Insmed presented at about a month ago?
I wonder if we can look forward to another initiation of coverage based upon the One-on-One Day from February 25? (See below)
Leerink Swann Global Healthcare Conference 2013 on Wednesday, February 13, 2013 at 1:30 p.m. (ET) at the Waldorf Astoria Hotel in New York City
The Canaccord Genuity Orphan Drug One-on-One Day on Monday, February 25, 2013 at the Omni Berkshire Place in New York City